Humacyte Inc (HUMA) stock price

Humacyte Inc (HUMA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.59 (+1.83%), Market cap $0.20B, 52-week low–high $0.57 ~ $2.77.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Humacyte Inc are updated in real time on BlackAll Trade.

Humacyte Inc financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Humacyte Inc (HUMA) stock price?

Humacyte Inc trades at $0.59 (+1.83%). Real-time quotes and charts are available on BlackAll Trade.

What is the Humacyte Inc (HUMA) market cap?

Humacyte Inc has a market cap of about $0.20B.

What does Humacyte Inc (HUMA) do?

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions a